Zobrazeno 1 - 10
of 36
pro vyhledávání: ''
Autor:
Jeong Eun Lee, Dong Il Park, Da Hyun Kang, Da Hye Lee, Jeong Suk Koh, Pureum Sun, Hyon-Seung Yi, Yoonjoo Kim, Chaeuk Chung, Song-I Lee
Publikováno v:
Cancer immunology, immunotherapy : CII. 71(3)
Background Immune checkpoint inhibitors (ICIs) have become the standard of care for a variety of cancers, including non-small cell lung cancer (NSCLC). In this study, we investigated the frequency of pseudoprogression and hyperprogression in lung can
Autor:
Andrea Widmer, Pascal Bezel, Stephan Wieser, Malcolm Kohler, Dieter Scholtze, Maya Vonow-Eisenring, Alan Valaperti, Benedikt Kowalski, Urs C. Steiner, Daniel Franzen
Publikováno v:
Cancer Immunology, Immunotherapy
Introduction Lung cancer is the leading cause of death by cancer. In recent years, immunotherapy with checkpoint inhibitors (ICI) emerged as a promising new therapeutic approach. However, a deeper understanding of the immunologic responses adjacent t
Autor:
Gigja Gudbrandsdottir, Øystein Bruserud, Karin M. Hjelle, Leif Bostad, Helene Hersvik Aarstad, Hans Jørgen Aarstad, Tor Henrik Anderson Tvedt, Christian Beisland
Publikováno v:
Cancer Immunology, Immunotherapy
Cancer Immunology and Immunotherapy
19–30
Cancer Immunology and Immunotherapy
19–30
Purpose An improved understanding of RCC immunology should shed further light on RCC tumor biology. Our objective was to study to what extent serum levels of the IL-6 family of cytokines at diagnosis were relevant to survival. Methods A total of 118
Autor:
Thomas Dreyer, Jens Peter Klussmann, Alexander Quaas, Nora Wuerdemann, Lisa Nachtsheim, Claus Wittekindt, Christoph Arolt, Stefan Gattenlöhner, Reinhard Buettner, Vanessa Ruesseler, Moritz F. Meyer
Publikováno v:
Cancer Immunology, Immunotherapy
Salivary gland carcinomas (SGCs) are rare and can be subdivided into distinct entities, some of which confer a poor prognosis. As targets for effective systemic therapy are warranted, some studies investigated the role of immune-checkpoint proteins P
Autor:
Mary Beth Henry, Mark R. Albertini, Richard K. Yang, Stephen D. Gillies, David M. Mahvi, Greg Hartig, Erik A. Ranheim, Jacquelyn A. Hank, Lakeesha Carmichael, Heather B. Neuman, Jacek Gan, Renae M Quale, KyungMann Kim, Thomas McFarland, Sharon M. Weber, Tracey L. Weigel, Hans Loibner, Cindy L. Zuleger, Paul M. Sondel
Publikováno v:
Cancer immunology, immunotherapy : CII. 67(10)
Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. Preclinical data in IC-treated tumor bearing mice with low tumor burden docu
Autor:
Seah H. Lim, Kaushal Parikh, C. Puccio, Arun Kumar, Jibran Ahmed, Hoo G. Chun, Asad Anwar, Michael P. Fanucchi
Publikováno v:
Cancer immunology, immunotherapy : CII. 67(9)
We carried out a retrospective cohort study on patients with metastatic non-small cell lung cancer (mNSCLC) to identify the peripheral blood count parameters associated with response to immune checkpoint inhibitors (ICIs). There were 17 males and 15
Autor:
Ciriaco Carru, Panagiotis Paliogiannis, Diego Cortinovis, Carlo Putzu, Francesca Colonese, Angelo Zinellu, Stefania Canova
Publikováno v:
Cancer immunology, immunotherapy : CII. 67(9)
Lung cancer is the most common malignancy worldwide. Despite significant advances in diagnosis and treatment, mortality rates remain extremely high, close to incidence rates. Several targeted therapies have been recently introduced for the treatment
Autor:
Hiromitsu Mimata, Yoichiro Kato, Wataru Obara, Isao Hara, Tomoaki Fujioka, Keiji Inoue, Renpei Kato, Fuminori Sato, Yusuke Nakamura
Publikováno v:
Cancer immunology, immunotherapy : CII. 67(9)
A phase I study using two peptide vaccines derived from M phase phosphoprotein 1 (MPHOSPH1) and DEP domain containing 1 (DEPDC1) demonstrated promising results for the treatment of advanced bladder cancer. Therefore, we further tested the ability of
Autor:
Giora Davidovits, Aviv Lutaty, Cynthia Botbol, Irit Arbel, Hagit Peretz Soroka, Tali Scheinmann, Shoval Tirman, Ruven Tirosh, Sonia Schneer, Michal Shteinberg, Shirley Abramovitch, Yochai Adir, Fernando Patolsky, Eyal Davidovits Davidovits
Publikováno v:
Cancer immunology, immunotherapy : CII. 67(7)
Lung cancer is the leading cause of cancer death worldwide. Survival is largely dependent on the stage of diagnosis: the localized disease has a 5-year survival greater than 55%, whereas, for spread tumors, this rate is only 4%. Therefore, the early
Autor:
Tessa Gargett, Paul Rolan, Joseph G. Altin, Antonio Ferrante, Michael P. Brown, Ines Atmosukarto, Katharine M. Gosling, M. Nazim Abbas, Christopher R. Parish, Jason D. Price, Andrew Ruszkiewicz
Publikováno v:
Cancer immunology, immunotherapy : CII. 67(9)
Introduction: In this phase I study using a 3 + 3 dose escalation design, the safety, dose-limiting toxicity (DLT), immunogenicity and efficacy of intravenous Lipovaxin-MM—a multi-component dendritic cell-targeted liposomal vaccine against metastat